{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:53:38Z","timestamp":1793710418024,"version":"4.6.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ymgme.2019.02.001","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T19:00:46Z","timestamp":1549825246000},"page":"406-412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers"],"prefix":"10.1016","volume":"126","author":[{"given":"Neil","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Levert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Hyland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nenad","family":"Blau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2019.02.001_bb0005","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/iub.1150","article-title":"Phenylalanine hydroxylase: function, structure, and regulation","volume":"65","author":"Flydal","year":"2013","journal-title":"IUBMB Life"},{"key":"10.1016\/j.ymgme.2019.02.001_bb0010","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1042\/BJ20110293","article-title":"Tetrahydrobiopterin: biochemistry and pathophysiology","volume":"438","author":"Werner","year":"2011","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymgme.2019.02.001_bb0015","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(10)60961-0","article-title":"Phenylketonuria","volume":"376","author":"Blau","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2019.02.001_bb0020","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13023-017-0685-2","article-title":"The complete European guidelines on phenylketonuria: diagnosis and treatment","volume":"12","author":"van Wegberg","year":"2017","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.ymgme.2019.02.001_bb0025","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jpeds.2007.02.017","article-title":"Assessment of tetrahydrobiopterin (BH4) responsiveness in phenylketonuria","volume":"150","author":"Fiege","year":"2007","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2019.02.001_bb0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1750-1172-8-103","article-title":"Tetrahydrobiopterin responsiveness in phenylketonuria: prediction with the 48-hour loading test and genotype","volume":"8","author":"Anjema","year":"2013","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.ymgme.2019.02.001_bb0035","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0140-6736(07)61234-3","article-title":"Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study","volume":"370","author":"Levy","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2019.02.001_bb0040","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s10545-007-0605-z","article-title":"The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study","volume":"30","author":"Burton","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2019.02.001_bb0045","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jpeds.2008.11.040","article-title":"Longo net al. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study","volume":"154","author":"Trefz","year":"2009","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2019.02.001_bb0050","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1017\/S0007114511000298","article-title":"Adjusting diet with sapropterin in phenylketonuria: what factors should be considered?","volume":"106","author":"MacDonald","year":"2011","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.ymgme.2019.02.001_bb0055","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10545-009-1067-2","article-title":"Disorders of biopterin metabolism","volume":"32","author":"Longo","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2019.02.001_bb0060","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s10545-012-9506-x","article-title":"An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia","volume":"35","author":"Opladen","year":"2012","journal-title":"J. Inerit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2019.02.001_bb0065","series-title":"Congenital Nueurotransmitter Disorders: A Clinical Approach","first-page":"39","article-title":"Tetrahydrobiopterin disorders presenting with hyperphenylalaninemia","author":"Burlina","year":"2014"},{"key":"10.1016\/j.ymgme.2019.02.001_bb0070","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ymgme.2010.09.005","article-title":"Membrane transport of sepiapterin and dihydrobiopterin by equilibrative nucleoside transporters: a plausible gateway for the salvage pathway of tetrahydrobiopterin biosynthesis","volume":"102","author":"Ohashi","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.02.001_bb0075","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11010-017-3060-7","article-title":"Organic anion transporters, OAT1 and OAT3, are crucial biopterin transporters involved in bodily distribution of tetrahydrobiopterin and exclusion of its excess","volume":"435","author":"Ohashi","year":"2017","journal-title":"Mol. Cell. Biochem."},{"issue":"Suppl 1","key":"10.1016\/j.ymgme.2019.02.001_bb0080","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ymgme.2005.09.002","article-title":"Delivery of exogenous tetrahydrobiopterin (BH4) to cells of target organs: role of salvage pathway and uptake of its precursor in effective elevation of tissue BH4","volume":"86","author":"Hasegawa","year":"2005","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.02.001_bb0085","unstructured":"European Medicines Agency. Guideline on Strategies to Identify and Mitigate Risks for First-in-Human and Early Clinical Trials With Investigational Medicinal Products. 2018 Available at https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-strategies-identify-mitigate-risks-first-human-early-clinical-trials-investigational_en.pdf (last accessed October 2018)."},{"key":"10.1016\/j.ymgme.2019.02.001_bb0090","series-title":"Chemistry and Biology of Pteridines and Folates","first-page":"199","article-title":"Sepiapterin administration raises tissue BH4 levels more efficiently than bh4 supplement in normal mice","author":"Sawabe","year":"2002"},{"key":"10.1016\/j.ymgme.2019.02.001_bb0095","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10545-008-0964-0","article-title":"Tetrahydrobiopterin in intestinal lumen: its absorption and secretion in the small intestine and the elimination in the large intestine","volume":"32","author":"Sawabe","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2019.02.001_bb0100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ymgme.2003.09.014","article-title":"Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration","volume":"81","author":"Fiege","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.02.001_bb0105","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ymgme.2008.04.007","article-title":"Cellular uptake of sepiapterin and push-pull accumulation of tetrahydrobiopterin","volume":"94","author":"Sawabe","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.02.001_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164305","article-title":"Tetrahydrobiopterin supplementation: elevation of tissue biopterin levels accompanied by a relative increase in dihydrobiopterin in the blood and the role of probenecid-sensitive uptake in scavenging dihydrobiopterin in the liver and kidney of rats","volume":"11","author":"Ohashi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2019.02.001_bb0115","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1515\/pteridines.1996.7.4.154","article-title":"A comparison of sepiapterin and tetrahydrobiopterin uptake by RBL2H3 cells","volume":"7","author":"Yamamoto","year":"1996","journal-title":"Pteridines"},{"key":"10.1016\/j.ymgme.2019.02.001_bb0120","author":"Kuvan\u00ae"},{"key":"10.1016\/j.ymgme.2019.02.001_bb0125","unstructured":"Kuvan\u00ae US Prescribing Information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/205065s000lbl.pdf (last accessed October) 2018)."},{"key":"10.1016\/j.ymgme.2019.02.001_bb0130","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ymgme.2009.01.002","article-title":"Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria","volume":"96","author":"Blau","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.02.001_bb0135","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1002\/ajmg.a.32562","article-title":"Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria","volume":"146A","author":"Lee","year":"2008","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgme.2019.02.001_bb0140","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1586\/eem.10.39","article-title":"Sapropterin dihydrochloride for phenylketonuria and tetrahydrobiopterin deficiency","volume":"5","author":"Blau","year":"2010","journal-title":"Exp. Rev. Endocrinol. Metab."},{"key":"10.1016\/j.ymgme.2019.02.001_bb0145","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13023-018-0911-6","article-title":"Diagnostic and therapeutic recommendations for the treatment of hyperphenylalaninemia in patients 0\u20134 years of age","volume":"13","author":"Muntau","year":"2018","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.ymgme.2019.02.001_bb0150","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.clinthera.2010.02.012","article-title":"Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults","volume":"32","author":"Musson","year":"2010","journal-title":"Clin. Ther."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218307315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218307315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:23:57Z","timestamp":1761089037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719218307315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1096719218307315"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.02.001","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}